Pharma Tech
Sep 1, 2026, 1:59 PM
Why CMC readiness is becoming central to biopharma licensing deals
CMC readiness is becoming critical in biopharma licensing as partners demand proof an asset can be transferred, scaled and supplied
Read moreNews
Google News
The Hindu
BioPharma Dive
BioPharma Dive
Global Agriculture
ActusNews.com
Pharma Tech
Sep 1, 2026, 1:59 PM
CMC readiness is becoming critical in biopharma licensing as partners demand proof an asset can be transferred, scaled and supplied
Read morePharmaShots
Sep 1, 2026, 12:30 PM
Shots: Ref: Cortec | Image: Cortec | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post CorTec Receives Second FDA Breakthrough Device Designation for Brain Interchange system appeared first on PharmaShots.
Read morePharmaShots
Sep 1, 2026, 12:30 PM
Shots: Company: Biocon Product: Yesafili Active Ingredient: Aflibercept Reference Product: Eylea Reference Product Company: Bayer Disease: All Approved Indications Date: Aug 03, 2026 Shots: Company: Fresenius Kabi & Dr Reddy’s Laboratories Product: Rituximab Active Ingredient: Rituximab Reference Product: Rituxan Reference Product Company: Genentech & Biogen Disease: All Approved Indications Date: Aug 03, 2026 Shots: Company: Samsung Bioepis Product: Opuviz Active Ingredient: Aflibercept Reference Product: Eylea Reference Product Company: Bayer Disease: All Approved Indications Date: Aug 10, 2026 Shots: … The post Key Biosimilars Events of August 2026 appeared first on PharmaShots.
PharmaShots
Sep 1, 2026, 11:30 AM
Shots: Ref: Globenewswire | Image: AstraZeneca & Hutchmed | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post HUTCHMED Reports P-III Trial Data on Orpathys + Tagrisso for Previously Untreated MET-Overexpressing EGFRm NSCLC appeared first on PharmaShots.
Read morePharma Tech
Sep 1, 2026, 11:05 AM
These White House deals will require the nine midsize pharma companies to provide MFN prices to state Medicaid programmes nationally.
Read morePharmaShots
Sep 1, 2026, 10:30 AM
Shots: Ref: Globenewswire | Image: Novartis | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Novartis Reports P-III (REMODEL-1/-2) Trial Data on Remibrutinib for Relapsing Multiple Sclerosis appeared first on PharmaShots.
Read more